BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...
Hausleiter J. First commercial multicenter experience with the PASCAL transcatheter valve repair system for tricuspid regurgitation. Presented at: TVT 2021. July 21. 2021. Miami, FL. MIAMI, FL—The ...
Tricuspid valve repair with the experimental Pascal device sustained significant early reductions in tricuspid regurgitation and improved quality of life, 1-year results from the CLASP-TR study show. ...
Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...
Transcatheter tricuspid valve repair with the PASCAL system appeared safe, with preliminary promise in reducing regurgitation and symptoms, the early feasibility CLASP TR trial showed. Major adverse ...
One of the biggest stories coming out of Transcatheter Cardiovascular Therapeutics’ annual meeting in Boston this weekend focuses on the success of Edwards Lifesciences Corp.’s freshly FDA-approved ...
SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...
BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results